Patents Examined by George C. Elliott
  • Patent number: 6194159
    Abstract: A new method for the identification of useful promoters is disclosed. The method is capable of identifying bacterial promoters sensitive to a particular cellular insult and may be modified to identify promoters sensitive to herbicides and crop protection chemicals. Constructs comprising promoters upstream of a luminescent reporter genes are placed in transformed hosts. Transformants grown in liquid media to a predetermined growth stage and contacted with a cellular insult are assessed for regulatory region activity by measurement of the resulting change in bioluminescence. The method is able to identify promoters undetectable by standard methods.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: February 27, 2001
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Robert Alan LaRossa, Tina Kangas Van Dyk
  • Patent number: 6194150
    Abstract: Nucleic acid molecule which blocks synthesis and/or expression of an mRNA encoding B7-1, B7-2, B7-3 and/or CD40.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: February 27, 2001
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Thale Jarvis, James McSwiggen
  • Patent number: 6190869
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein kinase C-theta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein kinase C-theta. Methods of using these compounds for modulation of Protein kinase C-theta expression and for treatment of diseases associated with expression of Protein kinase C-theta are provided.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: February 20, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6190857
    Abstract: Disclosed are diagnostic techniques for the detection of human disease states that affect gene expression in peripheral leukocytes. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. The invention further relates to methods for detection of protein species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. Genetic probes, antibody probes and methods useful in monitoring the progression and diagnosis of two specific disease states, prostatic cancer and breast cancer, are described.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: February 20, 2001
    Assignee: Urocor, Inc.
    Inventors: David Ralph, Gang An, S. Mark O'Hara, Robert Veltri
  • Patent number: 6187586
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Akt-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Akt-3. Methods of using these compounds for modulation of Akt-3 expression and for treatment of diseases associated with expression of Akt-3 are provided.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert, Richard A. Roth
  • Patent number: 6187559
    Abstract: The invention relates to novel genes for human phospholipase D (PLD2), proteins produced by the gene, variants of PLD2, antibodies to the protein, assays using the protein and antibodies, and methods of treating PLD-dependent diseases using the compositions of the invention.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: February 13, 2001
    Assignee: Novartis AG
    Inventors: Paul Michael Steed, Daniel James LaSala
  • Patent number: 6184037
    Abstract: Compositions of chitosan-based compounds and nucleic acid or oligonucleotide which are capable of delivery to a cell. Methods of preparation of the compositions. Methods of administering the compositions in vitro to cells in culture or in vivo to an organism.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: February 6, 2001
    Assignee: Genemedicine, Inc.
    Inventors: Alain Rolland, Russell J. Mumper
  • Patent number: 6184212
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: February 6, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Loren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia, Lex M. Cowsert
  • Patent number: 6180348
    Abstract: This invention relates to methods of preparing oligonucleotide libraries, isolating oligonucleotide aptamers to target molecules from the libraries, and using the aptamers to purify target molecules by affinity separation. Specific oligonucleotide aptamers to erythropoietin were isolated accordingly.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: January 30, 2001
    Inventor: Weihua Li
  • Patent number: 6177274
    Abstract: A compound for targeted gene delivery is provided consisting of polyethylene glycol (PEG) grafted poly(L-lysine) (PLL) and a targeting moiety, wherein at least one free amino function of the PLL is substituted with the targeting moiety, and the grafted PLL contains at least 50% unsubstituted free amino function groups. TM is preferably lactose or galactose which are capable of specifically targeting a hepatoma cell or a liver cell. The new synthetic carriers with various substitution ratios of targeting moiety-PEG were characterized using NMR spectroscopy. The new polymeric gene carriers of this invention are capable of forming stable and soluble complexes with nucleic acids, which in turn are able to efficiently transform cells. PEG attached to the PLL gives better solubility properties to the gene/carrier complex and improved transfection efficiency without considerable cytotoxicity. Methods of preparing and using the targeting moiety-PEG-PLL as gene carriers to efficiently transfect cells are disclosed.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: January 23, 2001
    Assignee: Expression Genetics, Inc.
    Inventors: Jong Sang Park, Young-Hun Choi, Feng Liu
  • Patent number: 6174870
    Abstract: Oligonucleotides and oligonucleotide analogs are provided which are capable of antisense interaction with messenger RNA of papillomavirus. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and therapeutics as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotide or oligonucleotide analog is provided which is hybridizable with a messenger RNA from a papillomavirus. The oligonucleotide or oligonucleotide analog is able to inhibit the function of the RNA, and accordingly is useful for therapy for infections by such papillomavirus. In accordance with a preferred embodiment, portions of the papillomavirus are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E1, E7, E6 or E6-7 messenger RNAs.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: January 16, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Christopher K. Mirabelli, David J. Ecker, Lex M. Cowsert
  • Patent number: 6174872
    Abstract: The invention is directed to a method for treating both the early and late phases of allergic asthma by introducing naked polynucleotides which operatively encode for the asthma-initiating antigen into the host. The antigen-encoding polynucleotides are administered to host tissues which contain a high concentration of antigen presenting cells (e.g., skin and mucosa) relative to other host tissues. Expression of the asthma-initiating antigen encoding polynucleotides of the invention inside of antigen presenting cells (without substantial secretion therefrom) induces antigen tolerance while suppressing IgE antibody formation in the early phase of the disease, and also suppresses cytokine-mediated eosinophil accumulation in the late phase of the disease. Devices and compositions for use in the methods of the invention are also described.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: January 16, 2001
    Assignee: The Regents of the University of California
    Inventors: Dennis A. Carson, Eval Raz
  • Patent number: 6174679
    Abstract: A human protein termed CIF150/hTAFII150 recognizes and selects TATA-less core promoters for cell cycle specific genes. Thus, CIF150/hTAFII150 plays an important and selective role in establishing gene expression patterns necessary for progression through the cell cycle. The CIF150/hTAFII150 gene and its expression products can be used to alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell and to treat disorders involving alterations in the regulation of mitosis or cell cycle progression.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: January 16, 2001
    Assignee: Chiron Corporation
    Inventor: Joerg Kaufmann
  • Patent number: 6171821
    Abstract: The invention features purified nucleic acid encoding a novel internal ribosome entry site (IRES) sequence from the X-linked inhibitor of apoptosis (XIAP) gene. The invention also features methods for using the XIAP IRES to increase cap-independent translation of polypeptide coding sequences linked to the XIAP IRES, and methods for isolating compounds that modulate cap-independent translation.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: January 9, 2001
    Assignee: Apoptogen, Inc.
    Inventors: Robert G. Korneluk, Martin Holcik, Peter Liston
  • Patent number: 6171857
    Abstract: The invention describes novel nucleic acids encoding the KARP-1 polypeptide, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.
    Type: Grant
    Filed: October 16, 1998
    Date of Patent: January 9, 2001
    Assignee: Brown University Research Foundatiion
    Inventor: Eric A. Hendrickson
  • Patent number: 6171860
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of RANK. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RANK. Methods of using these compounds for inhibition of RANK expression and for treatment of diseases associated with expression of RANK are provided.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: January 9, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brenda F. Baker, Lex M. Cowsert
  • Patent number: 6171795
    Abstract: Methods are provided for generating nucleic acid ligands of CD40ligand. The methods of the invention use the SELEX method for the isolation of nucleic acid ligands. The invention also includes nucleic acid ligands to CD40ligand, and methods and compositions for the treatment and diagnosis of disease using the nucleic acid ligands.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: January 9, 2001
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Alan J. Korman, Larry Gold
  • Patent number: 6172049
    Abstract: The present invention provides novel phosphonic acid-based cationic lipids of the general structure: or a salt, or solvate, or enantiomers thereof wherein; (a) R1 is a lipophilic moiety; (b) R2 is a positively charged moiety; (c) R3 is a lipophilic moiety of 1 to about 24 carbon atoms, a positively charged moiety, or a negatively charged moiety; (d) n is an integer from 0 to 8; (e) X− is an anion or polyanion; (f) Y is N or 0, and (g) m is an integer from 0 to a number equivalent to the positive charge(s) present on the lipid. The present invention further provides compositions of these lipids with polyanionic macromolecules, methods for interfering with protein expression in a cell utilizing these compositions and a kit for preparing the same.
    Type: Grant
    Filed: June 7, 1999
    Date of Patent: January 9, 2001
    Assignee: Promega Biosciences, Inc.
    Inventors: Brian Patrick Dwyer, Alexandre V. Lehedev, Bob Dale Brown, David Aaron Schwartz
  • Patent number: 6168950
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK1. Methods of using these compounds for modulation of MEKK1 expression and for treatment of diseases associated with expression of MEKK1 are provided.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: January 2, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William Gaarde, Donna T. Ward, Lex M. Cowsert
  • Patent number: 6169079
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5′-untranslated sequences, 3′-untranslated sequences, and intervening sequences.
    Type: Grant
    Filed: August 3, 1998
    Date of Patent: January 2, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Christopher K. Mirabelli